Home » Business Growth »

Business Model

Viropro’s business model relies on acquiring exclusive technological licenses and establishing strong partnerships with key local pharmaceutical partners through technological transfers of biogeneric therapeutic products.  The local manufacturing and marketing capabilities of its partners allow Viropro to reinforce its position in these emerging markets, namely South America, Africa, Asia and Eastern Europe. 

Viropro aims at providing its pharmaceutical partners access to state-of-the-art therapies with integrated turn-key solutions through comprehensive technological transfer programs going from development of industrial bioprocesses to complete training of technical teams.  Our approach will allow these partners to produce therapeutic products on an industrial scale and at affordable prices, in conformity with “current good manufacturing practices” (cGMP).  Through this unique business model, the company reinforces its strategic position in those emerging areas.

Further to minimising risks by sharing resources and common goals, Viropro generates revenues at each step of the technological transfer through fees and royalties, while securing a long-term stable business relationship with its partners.